drugset / Trial / NCT07091734

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

NCT07091734

Phase 2 Recruiting 32 enrolled University of Michigan
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake. Study Hypothesis: \- The clinical use of Tirzepatide in patients with lipodystrophy may lead to favorable outcomes through the reduction of caloric intake.

Timeline

Start
2025-09-08
Primary completion
2029-09
Completion
2029-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 15 mg

Indications